INOVIO PHARMACEUTICALS, INC.: 10-K filed 2025-03-18

Name: INOVIO PHARMACEUTICALS, INC.: 10-K filed 2025-03-18
Creator: INOVIO PHARMACEUTICALS, INC.

What INOVIO PHARMACEUTICALS, INC. reported in its annual report filed 2025-03-18 (fiscal FY 2024): 46 published measures, 94 facts as tagged in accession 0001055726-25-000012.

This filing

Form: 10-K (annual report)
Filed: 2025-03-18
Fiscal period: fiscal FY 2024
Accession: 0001055726-25-000012 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INOVIO PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2024-12-31	113,197,206	USD
At 2023-12-31	170,951,423	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2024-12-31	44,693,411	USD
At 2023-12-31	53,602,294	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2024-12-31	68,503,795	USD
At 2023-12-31	117,349,129	USD
At 2022-12-31	222,362,756	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2024-12-31	65,813,297	USD
At 2023-12-31	14,310,862	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-107,254,126	USD	366
2023-01-01 to 2023-12-31	-135,117,352	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-104,076,553	USD	366
2023-01-01 to 2023-12-31	-124,365,551	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	487,832	USD	366
2023-01-01 to 2023-12-31	320,898	USD	365

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	217,756	USD	366
2023-01-01 to 2023-12-31	832,010	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	51,475,546	USD	366
2023-01-01 to 2023-12-31	4,995,099	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	104,071,039	USD	366
2023-01-01 to 2023-12-31	87,355,875	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2024-12-31	-1,730,219,262	USD
At 2023-12-31	-1,622,965,136	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	27,160,863	shares	366
2023-01-01 to 2023-12-31	22,173,662	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	27,160,863	shares	366
2023-01-01 to 2023-12-31	22,173,662	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-3.95	USD/shares	366
2023-01-01 to 2023-12-31	-6.09	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-3.95	USD/shares	366
2023-01-01 to 2023-12-31	-6.09	USD/shares	365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2024-01-01 to 2024-12-31	USD	366
2023-01-01 to 2023-12-31	USD	365
2022-01-01 to 2022-12-31	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2024-12-31	3,659,818	USD
At 2023-12-31	4,960,986	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	6,595,108	USD	366
2023-01-01 to 2023-12-31	11,072,486	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-112,398,922	USD	366
2023-01-01 to 2023-12-31	-143,940,028	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2024-12-31	97,830,050	USD
At 2023-12-31	153,113,100	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2024-12-31	35,325,584	USD
At 2023-12-31	42,570,228	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2024-12-31	1,199,056	USD
At 2023-12-31	2,405,228	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	112,616,678	USD	366
2023-01-01 to 2023-12-31	144,772,038	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	75,620,340	USD	366
2023-01-01 to 2023-12-31	86,676,563	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2024-12-31	36,099,991	shares
At 2023-12-31	22,793,075	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2024-12-31	65,813,297	USD
At 2023-12-31	14,310,862	USD
At 2022-12-31	46,329,359	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2024-12-31	1,799,362,625	USD
At 2023-12-31	1,740,954,074	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2024-12-31	-675,667	USD
At 2023-12-31	-662,601	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2024-12-31	8,113,840	USD
At 2023-12-31	9,491,735	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2024-12-31	11,865,000	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2024-12-31	20,122,265	USD
At 2023-12-31	25,812,899	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2024-12-31	16,462,447	USD
At 2023-12-31	20,851,913	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2024-12-31	1,979,654	USD
At 2023-12-31	605,315	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2024-12-31	2,517,465	USD
At 2023-12-31	5,414,097	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2024-12-31	1,704,000	USD
At 2023-12-31	1,993,000	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-107,254,126	USD	366
2023-01-01 to 2023-12-31	-135,117,351	USD	365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-107,267,192	USD	366
2023-01-01 to 2023-12-31	-135,081,212	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	36,996,338	USD	366
2023-01-01 to 2023-12-31	47,582,104	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	1,752,147	USD	366
2023-01-01 to 2023-12-31	2,621,649	USD	365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	0	USD	366
2023-01-01 to 2023-12-31	145,417	USD	365

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	177,833	USD	366
2023-01-01 to 2023-12-31	1,222,789	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-3,163,711	USD	366
2023-01-01 to 2023-12-31	-4,711,596	USD	365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	0	USD	366
2023-01-01 to 2023-12-31	-32,046	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	533,487	USD	366
2023-01-01 to 2023-12-31	1,066,975	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	36,033,473	USD	366
2023-01-01 to 2023-12-31	5,461,745	USD	365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-12-31	-1,206,172	USD	366
2023-01-01 to 2023-12-31	-9,332,988	USD	365

Inspect the source

Entity: INOVIO PHARMACEUTICALS, INC. / CIK 0001055726
Captured: 2026-09-20T05:17:43.559Z
SEC response SHA-256: 9bfa830827e08b2d190e6d0b4ce0274a3c0d8852b6e536b16b5cfeadcaa54cf9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001055726.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))